Last updated 2026-11-10
- Acquired by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.) for $4.5M, Jun 2026
- Raised $9.3M grant led by European Innovation Council (EIC), Dec 2021
- Raised $8M Series C led by Triventures, Sep 2017
Total raised
$22.3M
Last: Grant 2021-12
Stage
Acquired
Founded
2010
Headcount
11
HQ
Kfar Saba, Israel
Sector
Health Tech & Life Sciences
About
Colospan is a clinical-stage medical device company focused on developing proprietary technology for colorectal surgery. Its flagship product, CG-100, is a temporary intraluminal bypass device designed to protect colorectal anastomoses and reduce the need for diverting stomas. The company aims to improve clinical outcomes, simplify recovery, and reduce complications for patients undergoing colorectal surgery. Colospan's CG-100 is CE-marked in the EU and Israel, has received FDA Breakthrough Device Designation, and is approved for investigational use in the US.
Funding history · 6 rounds · $22.3M total
6 events/rounds · $22.3M Total Funding: $10.5M in Private Equity
Jun 2022
Grant
$2.5M
EU CORDIS — Horizon Europe (CG-100)
Dec 2021
Sep 2017
Mar 2017
Grant
$54K
EU CORDIS — H2020 (CG-100)
Feb 2016
Sep 2015
★ VI VenturesDocor International ManagementAnatomy Medical Technology FundDocor (subsidiary of Van Leer Group Foundation)Anatomy Fund (part of Clal Biotechnology Industries)
Offices
Kfar Saba, Israel · HQ / main office
Q&A
- What is Colospan's primary focus?
- Colospan is a clinical-stage medical device company that develops proprietary technology for colorectal surgery, specifically focusing on preventing anastomotic leaks and reducing the need for diverting stomas.
- What is Colospan's flagship product?
- Colospan's flagship product is CG-100, a temporary intraluminal bypass device designed to protect colorectal anastomoses.
- What is the regulatory status of Colospan's CG-100 device?
- The CG-100 device is CE-marked in the EU and Israel, has received FDA Breakthrough Device Designation, and is approved for investigational use in the US.
- When was Colospan acquired and by which company?
- Colospan was acquired in June 2026 by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.) for $4,500,000.
- How much funding has Colospan raised in total?
- Colospan has raised a total of $22,304,857 in funding.
- When did Colospan receive its most recent grant funding?
- Colospan received a grant of $9,300,000 in December 2021 from the European Innovation Council (EIC).
- Which investors participated in Colospan's A Round funding?
- In September 2015, Colospan raised $2,000,000 in an A Round, with VI Ventures as a lead investor.
Team · 7
Boaz Assaf
Founder · Founder & CEO
Eyal Teichman
Founder · CTO
Emilia Ozer
VP Quality
Shelly Sharon
VP Clinical Affairs EMEA
Orit Tal
VP Regulatory Affairs
Gregory D. Casciaro
Board Member
Michal Geva
Board Member
Sectors & technology
Primary sector
Health Tech & Life Sciences
Target customers
Business model
B2B
Highlights
Patents
Tags
gastroenterologysurgerymedical-devicessurgical-instrumentssurgeonspreventiontreatmentscancercolonoscopyhospitals
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | colospan.com/ |
|---|---|
| linkedin.com/company/68366723 |
Identifiers & details
| Legal name | Colospan Ltd. |
|---|---|
| Founded | 2010-12 |
| Employees (exact) | 11 |
Acquisitions & public offerings
Acquired by Eocene Ltd. (formerly Galmed Pharmaceuticals Ltd.) 2026-06 $4.5M
Radar intelligence
Patents
| EPO | 4 |
|---|
Web history (Wayback)
| Domain | colospan.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514525971 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2010-11-28 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2026 |
| Active charges / liens | 0 |
| Registry events | 2 — annual_report (1), people (1) |
| Registered address | עתירי ידע 21 כפר סבא |
Recent registry events
| Date | Event |
|---|---|
| 2026-02-10 | דו~ח שנתי |
| 2026-02-08 | עדכון בעלי תפקידים |